The FINANCIAL — Teva Pharmaceutical Industries Ltd., announced the launch of a generic equivalent of Ortho Tri-Cyclen Lo (norgestimate/ethinyl estradiol) tablets in the United States. Teva’s Tri-Lo-Sprintec (norgestimate and ethinyl estradiol tablets, USP) is an oral contraceptive, available in a 28-day blister pack dispenser, used by women to prevent pregnancy.
As one of the leading global pharmaceutical companies, Teva is committed to care in women’s health with a portfolio including contraceptive products and other therapies, according to Teva.
Ortho Tri-Cyclen Lo (norgestimate/ethinyl estradiol) tablets, marketed by Janssen Pharmaceuticals, Inc., had annual sales of approximately $488 million in the United States, according to IMS data as of October 2015.
Discussion about this post